News
BOVNF
2.980
NaN%
--
BioInvent Posts Strong Interim Data for BI‑1808 and KEYTRUDA Combo in Recurrent Ovarian Cancer
TipRanks · 3d ago
BioInvent Steps Up Investor Outreach with Series of 2026 Healthcare Conferences
TipRanks · 12/18/2025 13:45
BioInvent’s BT-001 Clinical Trial Termination: Implications for Investors
TipRanks · 12/14/2025 16:31
BioInvent Reports Promising Phase 2a Trial Results for NHL Treatment
TipRanks · 12/08/2025 13:38
BioInvent’s BI-1808 Shows Promise in Early Phase 2a CTCL Trial
TipRanks · 12/07/2025 13:32
BioInvent Publishes Promising Early Data for BI-1607 in Cancer Treatment
TipRanks · 11/18/2025 13:32
BioInvent’s BI-1808 Receives Positive EMA Opinion for Orphan Drug Designation
TipRanks · 11/17/2025 08:32
BioInvent’s BI-1910 Shows Promise in Phase 1 Trials for Solid Tumors
TipRanks · 11/07/2025 14:34
BioInvent to Present Promising Phase 2a Data at ASH 2025
TipRanks · 11/03/2025 14:30
BioInvent to Present Promising BI-1808 Data at ASH 2025
TipRanks · 11/03/2025 14:30
BioInvent’s Earnings Call: Strategic Gains Amid Financial Challenges
TipRanks · 10/31/2025 00:09
BioInvent’s Strategic Focus on Lead Cancer Therapies
TipRanks · 10/30/2025 04:08
BioInvent Prioritizes Advanced Programs to Boost Cancer Therapy Development
TipRanks · 10/29/2025 07:30
BioInvent to Present Interim Report for January-September 2025
TipRanks · 10/27/2025 14:33
BioInvent and Transgene’s BT-001 Shows Promising Results in Cancer Treatment
TipRanks · 10/20/2025 07:03
BioInvent and Transgene Reveal Promising BT-001 Clinical Data at ESMO 2025
Barchart · 10/14/2025 02:10
BioInvent Launches Phase 2a Trial for BI-1206 in NSCLC and Uveal Melanoma
Barchart · 10/09/2025 01:36
BioInvent to Present Phase 1 Data for BI-1910 at SITC
Barchart · 10/04/2025 08:46
More
Webull provides a variety of real-time BOVNF stock news. You can receive the latest news about Bioinvent Intern through multiple platforms. This information may help you make smarter investment decisions.
About BOVNF
BioInvent International AB is a Sweden-based biopharmaceutical company, that develops antibody-based drugs for cancer therapies, with two ongoing programs in Phase l/ll clinical trials for the treatment of haematological cancer and solid tumors. The Company’s operational activities are focused on expanding the clinical development of human antibodies, such as BI-1206, BI-1808, BI-1607 and BT-001. The Company has one wholly-owned subsidiary BioInvent Finans AB, which engaged in the administration of warrants issued by the Company.